Anixa Biosciences (ANIX) Gross Profit (2010 - 2023)

Anixa Biosciences' (ANIX) quarterly Gross Profit came in at $49000.0 in Q2 2023, up 5000.0% on a QoQ basis from -$1000.0 in Q4 2021.

Anixa Biosciences (ANIX) Gross Profit (2010 - 2023) Analysis & Trends

Anixa Biosciences (ANIX) has 11 years of Gross Profit data on file, last reported at $49000.0 in Q2 2023.

Quarterly Gross Profit changed N/A year-over-year to $49000.0 in Q2 2023, while the trailing twelve-month figure through Oct 2023 was $48000.0 (changed N/A YoY) and the FY2023 annual result came in at $49000.0, changed N/A from the prior year.
Gross Profit advanced to $49000.0 in Q2 2023, from -$1000.0 in the prior quarter.
In the past five years, Gross Profit ranged from a high of $128000.0 in Q1 2021 to a low of -$1000.0 in Q4 2021.
A 3-year average of $64937.5 and a median of $66375.0 in 2019 frame the typical range for Gross Profit.
The widest YoY moves for Gross Profit: up 66.41% in 2019, down 66.41% in 2019.
Tracing ANIX's Gross Profit over 3 years: stood at $83750.0 in 2019, then tumbled by 101.19% to -$1000.0 in 2021, then soared by 5000.0% to $49000.0 in 2023.
The last three Gross Profit figures came in at $49000.0 (Q2 2023), -$1000.0 (Q4 2021), and $128000.0 (Q1 2021), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Anixa Biosciences	123.62 Mn	123.62 Mn	-

Download Data